Adaptive Biotechnologies Stock Declines Amid Competitive Concerns
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 05 Dec 25
Source: Fool
Adaptive Biotechnologies Corp's stock fell 15.06%, hitting a 5-day low as competitive pressures mount.
The decline follows Natera Inc.'s acquisition of Foresight Diagnostics, raising concerns about Adaptive's market position in precision oncology.
Analysts suggest that while Adaptive has not yet faced direct competition from Foresight, the acquisition could limit potential M&A opportunities for the company.
Analyst Views on ADPT
Wall Street analysts forecast ADPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADPT is 20.25 USD with a low forecast of 20.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 18.500
Low
20.00
Averages
20.25
High
21.00
Current: 18.500
Low
20.00
Averages
20.25
High
21.00
About ADPT
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
